CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 8-K Event Executive or director change
- 4 Open-market sale General Counsel sold 5,000 shares at $21.55 ($107,753)
- 4 Open-market sale General Counsel sold 5,000 shares at $25.32 ($126,600)
- 8-K Event Shareholder vote results
- 4 Open-market sale Director sold 9,969 shares at $25.05 ($249,723)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 16,498 shares (grant or award)
- 4 Grant or award Director acquired 16,498 shares (grant or award)
- 4 Option exercise President and CEO acquired 27,410 shares (option exercise)
- 4 Option exercise Chief Financial Officer acquired 14,897 shares (option exercise)
- 4 Option exercise Director acquired 379,066 shares (option exercise)
- 4 Grant or award EVP of R&D and CMO acquired 200,534 shares (grant or award)
- 8-K Event Executive or director change
- 4 Open-market sale General Counsel sold 5,000 shares at $30.00 ($150,000)
- 8-K Event Other events
- 4 Open-market sale General Counsel sold 5,000 shares at $28.30 ($141,476)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
Page 20 of 30 · 587 filings